MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Veracyte DIO Ratio 2011-2026 | VCYT
Annual DIO Ratio Veracyte
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 68 | 37.5 | 68.9 | 49.8 | 64 | 81.2 | 74.3 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 81.2 | 37.5 | 63.4 |
Quarterly DIO Ratio Veracyte
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 68.1 | 70.8 | 54.7 | - | 37.6 | 37.6 | 50.6 | - | 67.8 | 69.8 | 63.8 | - | 49.8 | 50.3 | 52.6 | - | 61.2 | 66.9 | 74.6 | - | 80.9 | 85 | 79.2 | - | 74.8 | 72.5 | 59.5 | - | 24.1 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 85 | 24.1 | 61.5 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Xeris Pharmaceuticals
XERS
|
501 | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
UroGen Pharma Ltd.
URGN
|
377 | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
19.4 K | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | Canada |
 |
Agenus
AGEN
|
0.163 | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Завод ДИОД
DIOD
|
768 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
120 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Teligent, Inc.
TLGT
|
198 | - | -13.85 % | $ 16.1 M | USA |
 |
Amarin Corporation plc
AMRN
|
292 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
91.6 | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
315 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
303 | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.83 | 5.37 % | $ 4.53 M |  China |